| Molecular Formula | C16H15FN4O |
| Molar Mass | 298.31 |
| Density | 1.68±0.1 g/cm3(Predicted) |
| pKa | 11.56±0.40(Predicted) |
| Storage Condition | Room Temprature |
| In vitro study | BGB-290 has effective DNA trapping activity, IC50 is 13 nM. In the cell experiment, BGB-290 can inhibit the formation of intracellular PAR, IC50 is 0.24 nM. |
| In vivo study | In a MDA-MB-436 breast cancer xenograft model with BRCA1 mutation, oral administration at BGB-290 resulted in time-and dose-dependent inhibition of PARylation, which correlated with intratumoral drug concentration. In a patient biopsy-derived model of small cell lung cancer, BGB-290 had potent activity in combination with other chemotherapies. In C57 mice, BGB-290 can significantly penetrate into the brain tissue. By the oral route, the ratio of the exposure in the brain and in the plasma BGB-290 is about 20%. |